<SEC-DOCUMENT>0001193125-17-033319.txt : 20170207
<SEC-HEADER>0001193125-17-033319.hdr.sgml : 20170207
<ACCEPTANCE-DATETIME>20170207163832
ACCESSION NUMBER:		0001193125-17-033319
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20170207
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170207
DATE AS OF CHANGE:		20170207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		17579526

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d339006d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;7, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-31791</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3562325</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or Other Jurisdiction<BR>of Incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (678)&nbsp;620-3186 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;7 &#150; REGULATION FD</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;7, 2017, Galectin Therapeutics&nbsp;Inc. (the &#147;Company) issued the press release attached hereto as Exhibit 99.1.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this report is being furnished pursuant to this Item&nbsp;7.01 and shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or
under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND EXHIBITS</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:51.70pt; font-size:8pt; font-family:Times New Roman">Exhibit&nbsp;Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Galectin Therapeutics Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;7, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter G. Traber</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter G. Traber, M.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d339006dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g339006gale1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g339006gale2.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>First-in-human data presented at GTCBio 9th Immunotherapeutics&nbsp;&amp; Immunomonitoring Conference </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NORCROSS, Ga. (February 7, 2017)</B> &#150;<B> Galectin Therapeutics Inc. (NASDAQ: GALT</B>), the leading developer of therapeutics that target galectin
proteins, and the Providence Cancer Center today announced the presentation of preclinical and early clinical data from two investigator-initiated Phase 1 clinical trials of GR-MD-02 used in combination with approved cancer immunotherapies. Data
presented today at the 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> GTCBio Immunotherapeutics&nbsp;&amp; Immunomonitoring Conference in San Diego, CA by Dr.&nbsp;William&nbsp;L. Redmond, Providence Cancer Center, has been <U>posted</U>.
<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Preclinical results in mouse models of multiple types of cancers showed important anti-tumor and increased survival effects of combining
GR-MD-02 with different types of immune modulators, providing a compelling case for progressing studies into human patients with cancer&#148; said William L. Redmond, Ph.D., Associate Member, Laboratory of Cancer Immunotherapy, and Director, Immune
Monitoring Laboratory, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR. &#147;We are pleased that our translational medicine team is conducting two phase 1 clinical trials which were initiated under the direction of
principal investigator Brendan D. Curti, M.D., Director of the Providence Biotherapy Program at Providence Cancer Center.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GR-MD-02 was combined
with pembrolizumab (KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with advanced melanoma, and this study has been expanded to patients with oral/head and neck cancer (OHN) and non small cell lung cancer (NSCLC)
(<U>https://clinicaltrials.gov/ct2/show/NCT02575404?term=GR-MD-02&amp;rank=1</U>). Six subjects with advanced melanoma have been enrolled in the lowest dose cohort (2 mg/kg) with no safety concerns related to GR-MD-02. To date, one partial response
and one mixed response has been observed. Below is a chest CT scan of the patient with a partial response showing a marked reduction in tumor size at week 12 of therapy, after 3 doses of combined GR-MD-02 and pembrolizumab. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Baseline CT
Scan</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;<B>Week 12 Therapy CT Scan</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">


<IMG SRC="g339006gale3.jpg" ALT="LOGO">
</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GR-MD-02 was also combined with ipilimumab (Yervoy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in
patients with advanced melanoma (<U>https://clinicaltrials.gov/ct2/show/NCT02117362?term=GR-MD-02&amp;rank=6</U>). Seven subjects treated with the lowest two dose cohorts of GR-MD-02 (1 and 2 mg/kg) have been completed with no safety signals
identified due to GR-MD-02. In these low dose initial cohorts, there were no notable changes in the peripheral immune signature. Due to changes in the standard of care for metastatic melanoma (i.e., approval of KEYTRUDA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), recruitment has been slowed significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are encouraged by these early safety results
and look forward to further data on the safety and efficacy of GR-MD-02 used in combination with pembrolizumab (KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with metastatic melanoma, OHN, or NSCLC&#148;, said
Dr.&nbsp;Curti. &#147;While we cannot conclude from the one partial response in the pembrolizumab study that the response was related to GR-MD-02, it provides us with a clinically relevant signal to follow as GR-MD-02 doses are escalated. We hope to
report additional data in early 2018 when we anticipate a decision on progressing to phase 2. This decision will be based on the response rate of the combination of pembrolizumab with GR-MD-02 as compared to historical response rates to
pembrolizumab alone.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About GR-MD-02 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GR-MD-02
is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs including fibrotic disorders of the liver,
lung, kidney, heart and vascular system. The drug binds to galectin proteins and disrupts their function. Preclinical data in animals have shown that GR-MD-02 has robust treatment effects in reversing liver fibrosis and cirrhosis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics is
developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease, skin disease and cancer based on the Company&#146;s unique understanding of galectin proteins, which are key mediators of biologic function. Galectin
seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement
and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute (EACRI), Providence Cancer Center, Providence Portland Medical Center,
Portland Oregon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Providence Cancer Center, a part of Providence Health&nbsp;&amp; Services, offers the latest in cancer services, including diagnostic,
treatment, prevention, education, support and internationally renowned research. The Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute is a world-class research facility located within Providence Cancer Center. The
Institute&#146;s main area of investigation is cancer immunotherapy, a specialized field of study focused on triggering the immune system to fight cancer. Visit <U>www.providence.org/cancer</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward Looking Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events, and use words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148;
&#147;expect&#148; and others. They are based on current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding
the hope that Galectin&#146;s development program for GR-MD-02 will lead to a therapy for the treatment of fibrotic liver disease and/or an additional therapy </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
for the treatment of cancer when used in combination with pembrolizumab. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements
include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of its other drugs in development. Current clinical trial and any future clinical
studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of Galectin&#146;s drugs are subject to change at any time based on the
changing needs of the Company as determined by management and regulatory agencies. Regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional
capital that would allow it to complete its current trials or further develop and/or fund further studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by
its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin&#146;s business, see the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, and subsequent
filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Forward Looking Statements
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Galectin Therapeutics Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jessica Stanek
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GregoryFCA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jessicas@gregoryfca.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">215-297-3606 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Providence Cancer Center, Providence Portland
Medical Center Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jean Powell Marks </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">503-215-6433
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jean.marks@providence.org</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g339006gale1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g339006gale1.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ #<   $$ P$!               %!@@) 00' @,! 0 " P$!
M 0             ! @,$!@4'"/_" !$( $P!*P,!$0 "$0$#$0'_V@ , P$
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M2U%2CK)F??L2A2?Z?/E,92]DQ<+*L!<;4V2+X5?M#O\ AC3+KR^+8:4ZN^%
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MKKF4NI'\C2H> LHW=M!/H=,4HY$D3*H>DE3/S%Q@666/-HXVB[^=<4"9MO\
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MGPQF.2NP$T$PNPIXO#* LI'Z+A?W^F78 &:C3:33Y6PZ$^W3&1(J+'_H^%R
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MS')V9^L4X-6G@KS<YZYC[V0=Z.-=-!KI@<\R%G:":'N;9:T&/Q-J(03KR];
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M!"NO"K0ADVQQ@_VGQ//#_ME;_/Z,F^CZ_P" ?D]I0?G /WX[("_,-/N_(T
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MEX@D D@E^D$@DB@  @GEX@    &_<_"J2Q$@@E=X$DDDDCT(!WS- D@ D\
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M!"+]CJ$+!IA#!["CYZ]<#1*K7-B N61ZXH1(N7(\F8%HH$$B1@ ($&<45!"
M Z9Q[?YAOCT)V)TGG*6;)Z22?6S$_M6/TC33E".'@097)2Y(-+>-%U]=8.TX
M[=!XWAZ<'9P3R]9Z>/''LY8AV\>V/NW-;B=,[R@<T\-Q.GP^F*=C19RQXUYP
MP,\% *(U55S)FN-\GA"=>LPQV\"6GA'B'*/^"W@DN',.OC4>?TW(WUZM6%IY
M)AM@==R:<[],X]O'I@V=+@R2C@"MP^QXC)31B5VTQ$?3.YP"6!":89--A4"\
MJRH'?&%K9LC4OVNI4FC)X23Q6HC>"TQIX^O^\I_X_P"\NK&,DPIM9:Z)C YK
MP;362+4Q!^#$5#BS63A.U"C5LD@:+K":T!D0G('D-#31X$,LHFME%E$0'ARE
M[@A<I9$@40Q%2)TDN0P*@05Q$VJ+5:L"1<P1(0,+.7P)*&EF-)]@ )"$K)%0
M1#TZ]I/Q-Y#L+.X!=>^7HE LL-IAJ3I@;2'9 6PBTIFV#="):ZY($A=*%"K/
MU@O;@NA@%QX%]0)J<#5C8A5Q%7:M'4J Y>F4A8J-&73E! D8OJ?%*W<JA>4,
M5%"^?VKJX  E8B-?+<^F\TXTCR*38LNN#NR"Y;A3V<*X#ETX)@TD;RB, ]*+
M,&V]!&:H/,,'/!(2R:5&G2<(FR99IS!(&1=":/6/<@>N-V%BNR@D*#N0L625
MP6  @ .OE=L%90>$QVCA\08[]TC GATE<0':^RCQUD?2^O")8 OA#T,TC(%4
M@T0O$X,$2T>(4H6<T"<NK^"N<?0H!8M4Y!'DS0D*^S5$]'TR#]'T#<_?&-SI
M#94AN"NX WIG?R_*"P:T#@.Q@]0$<F\(/.,X-+IVE@D!I+@!2*5]9)H%(!QD
MY/L1\"I7EF#0TTYL$$#^W\3=W([!!E M@+NGG$=\*D 6?8$HLA_I^D24/)2M
MS65ZM*[7E44LDBBT(EUA\&'"G<,)[LZ(0" J(& '4ZW'I#GS8+0.'M)_H\4I
M%VM=XP!-AT8<)FHIXN%70 . GH4?HQH7S,LJ.3!5V[WB=F*MO-H]1'@\8*8D
M3B1L?SL*JJCS,X82-$$H$ P1F'S^6:@$0  +5#@-V3FOEYP'H@<IT#TF14C!
MB2SI/4)ZY!T-CJWD]"><V-3@1+,=L,%PG&(XC#10"J VYJ70&UFN&^.,6V7$
M@F7!E5C.,@<0>E)DIKB@Z8-TT3C-&- D.).-?ACP?94<J<0TY%<&1<RA="0(
M,'2.+:O(0XAU3R94"V0O,\,\6&!<I05$ "U5MTN\)426)B!%JI5Q+['*A7W-
M72$6./,Y9!*!2,%Z+?M,$*@ HX Z,7C)4XGD.LTZ@]&3$9"XIZ&W< -P.\&1
M0H@*2171+#F8([[T/(&@?75]\\!H-TP.-':<Y=O?@FB8&C>UG8[J9*)S:!CZ
M^N,8V T4#TTOC-.H/1F+H>@/T$SXOMS!AU>SQA\;VH\^-[&7Q/9STZIZ4R;)
MP/'_ %N6FCI4A4/V*75&;1Y,M^ D1*7.(,BA@P0*-  \N8<<89?#&Y6=*X/)
MN'QYY@I":/ 0<X2::&Y08=B3]<8R.^#VX#3VQR>0%5)ZYRZ;/2?A[2I'6PO9
M1$)':W%O>!=PJ*"F#:>,%6^M+0"-2ONM5J>%5$BTY#=@'341?D4FJ"ZK%NP)
MV<*RSUR;JJPQ6N7IHP:2*3_NI1H83; I+ES?A4'2TA.YVX&IF(4;D!EJ>/\
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M!"CAK.E>EYXD:.O3\KEVE\#P3HZLW 9D_'A9:@'AEVL-%5O-KP<[ST'V,R&
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MJ823:("D0)MMI&@=M&)3  E;V K'$?\ D/_$ "D0  (! @8! P4! 0
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#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g339006gale2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g339006gale2.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ #4  0 " @,!               &!P0% 0(#" $!  (# 0$
M              4& P0' 0+_P@ 1" !* /4# 1$  A$! Q$!_]H # ,!  (0
M Q    '[^!QXB<;*Y>3#C8LT@WX[+RXP           -1J[?S?SOJ$8AIGZ$
MZ%R^NZM:XY%RM\=#YQ.)^"Y          !P556;77=9M4>@Y:XKK0X_#2,2K
MT]XY,GT5U;ETBDXX          1:/DJPK-LWNU'2'<C=7';F_P!Z-JOF=UU'
MUO2NTP=S=$H=+ELD7(T;\ZF&2XW1 "RRMS;D>./#T)*: $^*8I=_J"EWK9X]
M61Y8F:R=>LVZU6+U67@%:LWE*>W_ -:YG\PEFD?(X641 ZEBF*0HN$JDLHJ,
M[FW,4W9&20$U(-4KK1]%Z+L\>IN?-'??,9(D98/1*O5%$N?627KU/G,7.QFF
M(9QR8IZ'H>IXF 9!BG8['4W!I#L2LU6EO?)/*.TYF''LOG4VGFGM/-/-V]:5
MVR$]L_S.[A5:<,HSCP-N1LQBU2&FY/,AA(3V,\ZF:=C!-:3XVQ3M1N=(T7HF
M;\8<WS7RO,3U;M_HEE6FL>V3Y           X>5[ 62HJA==#&26UV-.Q[+5
M;:N%.R,GP            .#DX><^>O0           #_Q  H$  " @,   0&
M P$        #! (%  $&$1(30!05%B(C)! Q4#3_V@ ( 0$  04"_C^L+=UH
MB/V(Z^+%RBJR(PCQ]RZZ!$%C=-V,H?;NV_>IKW\CRYF%"5-Q!_7N+BD>LCEY
MVT!FQ3'+GV(D!8K2A'8\UYQ3K'=/*^VM6  6BRM@76]9)G18?*HPFX#XQ>0O
M#)PSGS[$X74Y"IF[NSH'V?@T^:LF;.K Q=-7%%9M7E#R;KMG1VK=D*^1T[$K
M!AK YJU<L0Y.S9>N-+VP7*QNQ-T##EC#JI.6.NL@W8[ZR].RI3IRMC+,61"W
MZVCQ7[">_4CD<7(46UW31DHY%C5BIH<BQ\,0^VQ,481<K].0H&VPW#E;(='U
M<TQ75Y17035W(758ERG0'KR]%4FJ &O#A8-^/G^N7LE&FP^//=+NX1VTB"JL
M>N]*MK^XFRO]>[L$@=U=VR35!5&YM*ONA\_=;HMM2INO!XACD,AO!SP1O+BY
MQO";A(!:J'JV1RZ !*[4=*.W&6<[$6CRMAQ9?L%*Y9^P%7Q#;HD!JQQ2P&X2
MN>#9J1L1R?5O$G:[Y@$>-7(DP,VXTUW+<: V;@::YV] G\YAH\K47K")ZH[)
M/3R7ED.<=Y"60GD2X)N0"W@XF6YU3>H._P#'2KNU\U([$X\N25D4/FO7EYWD
MC2><I"UEB6NA9^IJN3W-[EAE!1@\\>C)7.ZK;=0;(KJ#Q^7Z31&.?Z31&*&_
M7,_218W8'=T3?07 I$ND=_JYT-)(V];R,LU//4S<\I/!ZMA"(X^XLN>5>VQ1
M6BV_19C@:ZQ/B/,[\1C@*'^L_\0 /!   @$" @4)!04) 0       0(#  0%
M$1(A,4%1!A,B,D!A<9&A%"-"@;%28G)S@A D0U!CDL+1\>'_V@ ( 0,  3\!
M_9W"H<$Q2:)IQ:,D**7+/T>B!GOK#\/EQ$S+$ZH8(C*=+>!N7OJVP7$+NU]L
MMH>=BTBN08:?1V]&I898',<T;1.-S J?(]JLK*XQ"X2VMDTY&\E7>S'<!6%<
MG[+#%60J+BZ&V5AL_ N[QJ7)D9#U75E/@1E6#_N6-26K]$/SMOK[^KYY5R:S
MCP]X=C0SRH1PUU=6EI?1\W=1"4<=C#P;:#6,8'+AC<ZF<MHQR#Y=4_9;OX'?
MVG L?LL)A,;63O+(<Y) RZ^"@'<.&^H>56$S]'G6@/\ 54_5:2XAF72AD65>
M*D$?^5RFM6AN8<1AU:9 ;+<Z[#\]E8/=K))<,NH786<#@_4E3Y-D<^%"7Y4X
MCGB>"4:<3C(J=G_:Q2P;#KMX=L9Z4;?:0[/+8>SX5;7-S=I[-9B],/2:-NJ?
M'9QI[.]R]YR4M\ONN%/HU3V%IE[W!+VQ/VH6YU/(C6/ TML87TL,Q#-Q_#?W
M$G]KY*WG1QF22-[+%HCTAEIY9,.!(^A6K&X]BN0NGG'I:CNR.KU'J :CEU#7
M4;URGMQ-9QW/QV[ ?H/^CEV?D0H'MLGQ#(?+-:>GJZ@@F!$T*RCO4$U=89 P
MT5+!1L5ND!^ G6OTJ[LGM6U=*/CP\:PN]TT$+GIIL[Q4+[JQ,:6%W8.Z//R(
M[/R*N EY<6YVR)I+^DKGZ4U.*D%21^E3VX8$$9@U<VTN'31SQ]3/,'A]TU8N
MEQ D\>QAK&\'?ZUC3\SA,^>V3)!\SV?#;QL/OK>[79$W2'%3J/I22+-$DT;:
M22*&!'?3"G6G2FBJ>Q2Y@>!AUAJ[CNKD]*T%W-ATVK6Q ^\NH^FL5RGO-.2*
MRC.J#IR?F'=\A]>T<F<?6URP^\;*!C[IS\!.U3W<.%99[->\>'&BM-'Z5S5"
M$^&5<H ;#%8KF!@)2H<C@PU:QWBG9I&:1VTF<YDG:3VG"N4EYAP$+_O-J/@8
M])/PM_B=56W*3"+K1SG]G<[5D&0'ZME>V6+#-;R$C\Q:N,6PNW&;WL9RW(=(
M^0K$.5A8-'AT>ANYY]OR39YT\CRN9)'+NVTD_P W_\0 /A   0,!! 8&!@@'
M 0       0(#! 4 $1(A!A,B,4%10$)Q<H&1$!0R4F%B(S-3DJ&QLM$5("1#
M@H/!\/_:  @! @ !/P'T7@9G("SM7I[3J&3)2IQ:L("=K/XVG3VX 9+B2L.K
M#8P\">=I%8@Q9!C/N:MP '=EG9IYIY.-EQ+B.:3TJ7+9ALE]]6%"?,GD+5&M
MRIY*<19CC<A/$?,>-D**5!?%)!'@;[58^N49J4C:+6K>R^7V_(6TA5BG(=2=
MEYEM8//9M&FRH3@<C.EL@[NJ?@1Q%J/7&JB-4Y<U)'5][N_MTFK4694G<8E(
M2T@;+:@;ASOL_HY5&<PT'P/LU#\E6=;<9.%UM32AP4"#;1B8AZ.]37L\()3\
M4*WCPWVK4=;"&$*WQ"IDGY#MMJ\1>GP]#3BV7$NMG"M&8(M29Z:A#0\,G$[+
MB?=6/_7]'J+[+,=0>DF)K-D+3[0[/*PE1!]7I$^D\,:"1^FS4V4/J:O$F7=5
MT:M7WLKK+EI>1@JM/N;/]U%SS7WD7J3XV-$2VXW4*)(!U:L6KQ7I/-((Y[L*
MK56+_$8*G0V4/H3<M!&8X^:3N/(FVXW;KKP?#T:*RBU-7&OV'TD_YC==X='T
ML)OC)X;_ -7H/Y69D2(YQ,/+:(Y*('ENLQ6Y3*L=PQ^\-DJ[P3<D^(OM2:Y'
MJ(U1^BDI&:#N5W3_ ,MI'2O4WO7&1='?.8'4<X]@/"PM1E%%3A$?: ='TJ9)
M89?'46$GQOMNL?0;(6MM25H44+1F".%J7/:KD)V'*N]8"<*A[PX. <^=I<5R
M%)<C."XMFX'@1P/B+:/M%VJQN3=ZSX='J$43(;\<CVTY=X9C\;.(4TM3:QA6
M@D$<B+'^2%*<@R6I+7M-G/XIW$>5M)([<F)'J;.>20;N1W>1R/*VBL'5M.35
MCZW8;[G$CM/2*_1R_?-C)O= VT>]=UNVQ%UXNN(M=:[TZ/CUZDNQ'TG5I5A'
M9OR[#9M"6D);0G"A   &ZX=)J- C327&OZ=_F/95WA^UI- J4>_Z'7)'61G^
M&^QARTFXQ71_K59FD5%X@-Q%]JAA'F;0-%<.%=0<Q79ZI&[L*]_E9MM#* VV
M@(0G< +NG;OATD#_Q !#$  " @ % 00$" L( P     " P$$  41$A,A%"(Q
M02,R46$&$!5"4G&!D20S0$-38G."DJ&Q%B!C<J+!T=(T4++_V@ ( 0$ !C\"
M^,4]I$V$8AM5$LT(IVQN(>['7WX23 ,X<Z$QLT[LSYSK/ACLMAA+.!$MT@4K
MT+P[PZZ8WI8#0^D!04?R_*B?8+:(^$?.,O( CS*<2.Z4UM>Z@)\8_P 4H]>?
MY8B8\8F)CZXZQA=H.LAP6ONZ']VL_=B&QX-K5V1]4ACDKL)1>[U2]QCX%'UX
MXF:*M#'J?-9$>)+_ -Q_*>2+:84$:)00G$#]*9F-=3F?/3'XD71[4'!?Z9TG
M^6-K )9?1,9&?NG#<O;UC0B")\UGT8/V3.O[V$@74JNZKK])6O+6/[0DH_<^
M(6+F1,)@A*/&)CPP+?!D=QH^QD>/V3X_;^3S#[9TN:86#E#)-B?6G9$1.G2)
MZX[GPGO1^T291_,<>ASG+;D?0LAV<Y_>C3&W,LO[GZ96VVCZ]Z^\O[L!<RIT
M3MG="Y+<,^T8/WQTT+') 2+('0PF.]&WKI]8EX>Z9]OQDCYM@)_C7WAG^'=@
MQ6SB.1G:R!$]D^1;2Z%]4XIYG.:H3<LR<"HZ21K&P+;4 GQWQR0O36)F8DM?
M+3#[&FXEAZ,/TCCT!"OWW$ _O8$[T .95;%JAF(+C0 N5'$L]L>0$.PX]QX^
M$.7AFBU#ED4"IS-!)#^&UV.D;/>U,1(8'NR$Z>_"+YQ%*TV'@1*&&*AE=[$R
MY(M]=)\>X=?(O'SQ4S&^X76+7*4PM(I6N <U4" CK,] B=9F?'&29?6N0FMF
MB\RET=F4TUE10MH$LR^E)Z3$Q/ATQ;&Q=5=3!+A!"H$M2<#/.ET+Z%^;*)Z>
MOIY=76&SHM"C:<_JK&2G[=(Q?3F8 G,LOOM182N-!%+1&S2F/;^#- =?.5E\
M5G)\M($#EJD,S.^8<T@VS$E7IU53.V6RL9,V'K Q,1MF9Z52&_VNB4L"XFQ7
MK@X/1%*G(<@%^#8$2 A+H>L>&,^HV+<-J9;&7S7"*REG/;D&XN5@^.R1TC2(
M]^*.6!;$:%C+;-\U=G7+-]9R%<8N\EERZSTF>G2<*RN+<=@/*3S*5=F5R<@6
MPK</-^BT+7PW>_#<KFW'8 R@,SA79E<G(RV=;AYOT40.OAN]^,RMU&PFQ3IV
M+2R)8M&2KJ-NPP+YI;=)TTG&3VIS11';74L/J,JI"')8H&6000=X3 3DH];U
M=)\=<%D<7/D[3+E7:Y;$DZ^;'-6P4]H$@V(A8;A$9*>7R@>JALF+; A M: [
M!:8])9 ?,W>MM\M=,5%_-VD?VZR/]/CU4PUS^H4C_3&_IO\ ,QB (OVD1W6?
M;&OOQI/=9[/*?>/_ !CD".X?^DO^)^*I,?IQC[^G^^#:TQ6L!U(SG:(Q[YG&
M66[CDU[M!UBT<D;%V!8NU9*-4%U+<DHZ0'6"C3KC*LM78=4F5_+%B (%VE<(
MA-*O.X3&'2UO+(:3,16QF66';8Y.=5J^9*98(2.,Q7/9;"3( $18U,(,8TB9
MV8^&=6OF#JEIU;*@IOKV'* F)J,AD$(% 65"S:#![W0ICIK@D7EKRK,,K7V?
M,:)1"%H)4;(=6CI!T61H2R#6.]M\8Q1[1;6IE9=GE06HV(F+3S@(1,;R(AD=
ML1'7=&/@G%Z1%0JS8["VS,=F)]1'9XL$$Z*F3UB-9ZS&&Y9E1\L>FS!O$7*F
MOS,$=DMUZ$P]\B&LSW"\(TQ1R+M'"S,+$$^5D,-74JQVB=)*)@3:X$JB)CK!
MG[,)EEUSD?"#+Y389:,")5W+RUIFR5J"%K8AC5#)1XCIKB]12939RZ4Q:&5,
M 0FPOD5M80P+.[]&9TQG%BX)#E7P@[)83?VR2:MZLK@;5ME$>@@QT(&%H/28
MUUQ6IUVA;?9DN[6,70E( 1F]YAJ*E](&-9U(CB(Q\)XL"IY;,H%&I'&[BJL&
MQ"Y$HAFP](+373&7+K0M&[)+RFZ$<QSG9K$E9$4S L(!.8'QG"!Y0U_LXVOX
M].<LQ6R$;O#ED(W;/'3%B6V5K'^SBJ^\IT7%@,Q8PDRSU8;"Y@MNNN/A%P-@
MUJHVZD.CJMUIM,RA%>?SQQO".[KU+3RG3)\R!BXNHRY"(2DR*RYUA"5'7[,4
MZ\LN$8\(TGQZ8M9=G&VI:R[:VM9-G9K:>1(,"YEUCI,Z%J$P,EWE:%'AC+)N
MD9VNQ5^9C(D6L+CCTC1GJ+3'0BB? BG%:S'S&<1?44%,?SC^[$Q.FF#0SU]O
M7WQY&/OB<&H_6"?OCRF/=,8K_J%+)^H!F?ZZ8:X@(Q4LF$ 1$F4!&Z8&"F(F
M=(]N*JH780=ZE\H4^T+$8L5?1R1+(#*(,(<K<!:%&^.F+(+I72['=[#8.%IF
M =,*G=I#MQJ@'K*2@9Z3[L-0M#K$UVUU6B2(3%<[$ 2]PD<$>@&!EL@MHSKB
MY4"G<<V@I+G<*TS''8ADJE6Y\2R9X6=V(U[OOP-RWJ*I8A.NS<4388(#K'D$
M;MQ3\T1*9\,5R:ES>TVDTU\(@4\]@MJH+>8[1DNF[RQ>L&4UARYIJOC9'C.L
M:P%G?TU@HE3%D,C)04'&F$3-"ZM5E@+!I+7W)9ZA/5#>1(3/34@Z:QNTQ?6M
M#A/+G]F=R"N-[N('Q"IAD[HXVKG6=/7^O 74K:"G;X"'B(LGC82RU$2+2-XE
MY^6+67BA_/5KILL+:N%FM\M%/&?)U,I2R-)B--O7%C,*T.:NMSC8K[(&THZ^
MO*HTD70]L;HC7O#,2.NN*ZU56%8M5SN!54*0;P*XMYGN8(1,$Y8Z;IZGAEIM
M*[V9-=-AC82N-D/_ #6PVB4N'INB(G3=BW:LT;JU4X4;/1I(C%LS&Y.U\PS;
M,=[KK&N'/?2N<%=:6M:"TD(RZ=L+C5T2;!G;NVZQ&Z.N+5FS1NK55E&_T:2D
M^T%L$E;7S#(@YB"ZZQKBFLD.F;;>(-D+D4LA1NGFG?W8@%GU'=ZNGGBM7G+[
MXON!997 EUXDPJ[.4IUL>CZ,7,06D][%!!T+<ONI?8KK)2-R^S;.86[W1Q-'
MD#Z]>D], S8:]PQ/&R-K GS$XB9T*)]DSA];S,.Y/T6#W@G^*,$LXVF$R)#/
MC!#TF/[H-">H3KI[8\QGW3&$9@KPF!$O\A]0G["Z?;AEPX_&>C5_DB>\7VET
M_=Q:T$BGL[H@0&3,IE91 B(]9F9QDKK5>U90>35<OU:G\)R.VM:^=1* !GL=
MB5C$LT*1*N&I;"Z9Q9:C.8+Y;FW52E-F$7%]BJH'N;>.1E@LZGM]2"\(P-[+
ME7:F:KMTZ]B( _D_-<NY%\A6ITXBA5=C=C=8:!KV]8F(G-W-#-EH*KE,);43
M:XGLJ';8U?HAF&^LN.O28.8C!561;HUHRUG)OK"6]N8+)1JB6 0RU"-==G75
M_2>F,B%]:^%U&:97VW969S!%)T0^YI(3Z,A'EB=)]?337IC-\H)4G?[<K,Z^
M8&.U&= FTBRD++1C:FS"ZX53"8$8@ (8VST1 T[T.:8 :65F+[-K^,-[9CBV
M!&O43+=TVZZX^$+7?*=869G#D[#LUUO2-"FGE4(_C/2I8/3K.V/=BFARGH:G
MM FNP! V-;+C&2W^.H$,Z^_&:N)-B$%EF6K!TI9Q,97;?-P+/3O$(O5X>.[I
MX8',\K0P,Q[$RI?RYXE7^4Z\0P16<%'<NJW;DM\]967=+NU1D,QK7ZE/FRW,
MZ"V$Q-G9L.J6P9@H/:O<ET<9Q[)'6&J:@VYD^G7%J*JR;K:GB)PA _,@H/KX
M=,7@KI>YKT@*DK29.*9,)TX]-1Z1.NNFF+:T)>YKUIA25),FE/,H_P 7IJ.@
MC.NNGABZFH&][$@Q*B]'+"4Q;X5W]-A%Q[>]II,]<9?*JUM0H8=E\VJ[:W%/
M9G)%'I8C>W>_YFZ- GKX:Y(P4O)2*V:@YPI,DJ*Q%.$B;(C2)+B/[NOCC)BX
M\PX$ULT%]BD%CT)6!JPF"8F->]QGTC7PC7"1VO&%CPCVF)AY@GT0M9$]8ED!
MOZ]>]U^*;]0=6Z?A"A\61'YT(\SB/&//^\^JZ"XH.0B?#NEW^[/M$M?OP(!$
M" 1 B,>$1'A^4RY4]FL3XD,>C9/^('M]\8_\>7#]-$\G^GUH^[&DUWQ/LX6?
M]<>CJ/\ K(.,?XCTQ!WV1^P5/_VS_K]^!6L1 !C01&-(B/J_]N#_Q  H$ $!
M  (" @(!! (# 0     !$0 A,4%187&!$$"1H?"QT<'A\5#_V@ ( 0$  3\A
M_"@50 JN@#E7HQ6!B()X T7IG0)%-J3NO6*F,H0V]A.:&'VSCX05:?3^JX,J
M/;_[,G+ QM<L<.A@?7PZ,#H?2443]S/ I)R1/YVLGFS[YA_R8:/>;T>3](8,
M&P0^\?9\AU3]3I\7N4-+<ET =909/9=?WQ8\/>?V33)/AZPQ_H+QEWDM[CX'
MRU'60ZRQ+RQ:H<TZT=U2@\</TZ_3]?T1!E$3::OG N_Z_?9B\ KA/J=KYSDS
MG4?2I>^'G#6;Z_"?9L7FYP/+.VF\[N4<QY_;9_#C,80'4GY&G]L<0:=)Z#9/
MR8..7%X'CNB #A$?NNM)WAWK#+<R>/JF-NY\G0J6BY;<$@_DB2M;"^.I@9<K
M&M0!46JD-8IOH]:R5L5#I<NZ?O,]L++42-''E09Q(SNB';CX9H!6EH5.[?@-
M%6QK$E2>6?@W@273RUPJ!=?+< ^0+O6C;<0 .C3KMA=@N@.B@[<-4.8MWF(3
MBP<%&Y VP[-,9-D7#RY$2L$0#1QPFN\;8<"]/0#49BVE7ERCNJP>^=)"54UZ
M%&PH9\')^*2:PV/?]L*/WAU;)KA\,QP( 1O^:?\ H]XHD38<+M/Y#[S:QO\
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M)B';K\+E9'NPN& </>'YBF4M!NZ/K7KT,#C<&&Z!_P#7_]H # ,!  (0 Q
M ! !#F@            6Q(P          "/"+N           000,L2 0"0
M ( 007. EP2 "2000 00>,7/\2" 2  202035_>=2"0 0"002001A-28
M       %.8P            ""H            #_Q  D$ $!  (" @(" @,
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MBAH 4<)\]8QY@IZX;/\ IQHN$IL<\K@J-8UN/\\0R%;.6DW/81>+KR=#Z/\
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7P0P#%CY<K=O[O'$=-(TVH# .RWN?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g339006gale3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g339006gale3.jpg
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M 0             !!@(#!00'"/_" !$( ,@!KP,!$0 "$0$#$0'_V@ , P$
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MV/3)"AC$M<W0SS3*^?GSRBIK#JKKLZP  5&@3.A^Q,GYMXB_3HP
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M3)E :2O  ]$"U#"YH KDE17A9HU$L'$U21HR^00W0>2I!@/TLD]<!A/'X9
MVX+1K-&FF3Z,M%>%DD*-2C699*5-R&0#&  +ST^+4/)$A@ !ZP$0*5)P-XWD
M!+)&@L,<#0)99CLIP[F+0 #?1NPYGE49R #V:,\B8TN6:4&5L0\LPCQ;Q>AE
M\HLFYE<HT -;GI**SSY,/ !^F_2)DI).3HK(J4G0Q"@L8=S4)G,K87'GJ<
MU<>G(RGF*9L #? WFAS012Q5 F*!+[$8_FM"#F:R)%!%$@!H4]8SD8',*GX
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MECKB'8Z$=[70E;C@^D?>(S9._K60N@4<8VW$04<CM<LC0M>@QWS?X<G!)*;
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M-+P[N!W=E=ISLKM.=E=ISLKM.<>\>W6IW0#_Q !$$  ! @(& PH(#@,
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M\*9M=/@+=1;' ENF9&9;'X8SQF251J0>)@1C-+YF/H7[9'@#;&_H9))LHXE
MXN'J.A&/.+NI/Z5>R?"1.FOK#YL68>YAJK?BGK]N+\HG^88VH "3NMG<OZNI
ML9JEBFEQ&@NY_&]@8L@91PY5&J $6Y-^G C+9D.N@Y'OT]^ HYV11XYC@,R_
MRF7M-;LK?2-#;07P1\#;EX ]QYX/+E;OT_%/?C,T:MF%B<MOU#!&YC-N5^_Y
M0P:>CBW0(\[,P9(H4[V?J>X#GA(Y*C>Q2@LK(.%QZX&;4,.XX:2FMN^>@Y_#
MU3@7T'Z3[O'$3Q(=Z_7D5\3XXD62EDF5>P].K,EN@>P)S8*VOKV+"V;K>X_7
MBTL"EN^-.(?VAI\,'=.R,+V0V/P.7#>4@C])^ '_ )8)I6R3>J);9#X$<UQE
MD5XI.F5;+;Y#]<:+DF^ 23W]$?\ 0<6/3[=?_4%5^T=E8VVHYD[+'S[(V?A?
M5R'+VB.#YM.']6*?:>RHH,]+Y-52V**S&E-I(G<6M(,Q-M.F ZET$B9AZ\3=
M^4\5F[QX8(8W0\.@!S=VEM#@]D\]"&7QMST-O#&G ? V&E]=>6HPN>*Q-N:V
M!/0J1I^G&[1BAM9@2P5K_P VP86%\0%$<$3%=,K7S<TZ?H'JX%W:&DCC+U$Y
MM:( :!2XT<^(/7&>F7-J9C.7WK2/SOF'(> Q%74PRNLWD=4F:X#Z[J7-;S;,
M!^C B4BZFWG$8DY;#A"Z8C>J@#HA-CRB7,1JY]5K#2_?B@R@;VM0-DL+*AY#
M-UTUOA"SM35JZK/';=Y^@DC]=;^(P])4HJR1=V8+)'_21'V#S_0<=]NM[_\
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M/!<ZIIV%^!.,EO/Q:2+GONLNEW)&6,<["Y.N-^SW"VR*,O#W#,P&7KBNT_\
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MJW!;*M9LXR=.09HQSQ]D%-4L11U8V7'*>D3_ '(V?NY[?)Z^!\,*S2@Q#LY
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MUF/1;],#RIF, N4CMNU4]X'4^.N)H/5C<,GAG'$.7M#&>QS^3QY^>N6^4^)
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M@#P*PE.\4WBF3D(G&JW!.C82H\LJ%TW<--G;)# H R7+C/?K?GC/))+P]G4
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MT]$XA2*8\;RFQ ":[WI_:Y$8WC)*D!.;5= S<PVGG%OU6V,ZU.[S"W!>6-O
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ME50WFPJQ4NSE4F*E13PQ6N!)(3K?K?N&)%)OM*=<H0YP]!&XU:0YR-\PT Y
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M%'==#U#$51=47&A@4*@[ =/G*-<OV"#1&FIYAHJHZ*A',#;:8B<D H/$>/\
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M670-G6 L#I'O\?\ EO/50[^]+_;_ (X)&>"?TE!3Z7PY+U$74EEV$_7F*GZ
MD>AJ.F_."AM(3==NEG(_]3Q4&U,!\NC#YBE<&@-BPI\67(8#*4*G139$_&F-
MSG9LT$4I?PDG,'4Y4+1.Q 9()C.2+IUL359KDQ039O31U=Q[*$VM3-"FAH*Z
M!8L!(>LVVU#:< PAM_#Y3&R9@CV43AU#/;$5?1IQPMVN8\#CN%0WB1\TL600
M>@T684+[4_\ (@_:CW$@%@F\$"_!-[Q'8JNUWU<%=R&/G 6:^.XQ&WC,GR.E
M@,6V=:H</<>5HQVA.FNLN,'4$;BJ@U[/_!>>CZ3U:)YROU<U=@1=CQTCTO<
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M^4J\WIBA2-N$+!T^=Y,(B)8-5"?KFID>_@_"?K8R#U%((J(Z1-(GS_#PXA1
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M;$D%+IXZ*84=*\:HDVH@0#XQV=-D^"&6EL7ZR2DY0LT%LD(7Y,B!-PS%'X"
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MAT3M= ^,2;RE.W1+=+5WK%#IU)WU!FKL]F-AXB=J7YX/5RQ"9"3B@<G?OSC
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M$X$QPNA)\#HY3'0?YTDO G(3923)VCJUKMI8^,US.O6R( %6%4:Z&.]2F?\
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M.C B$*Y(O$"<%GN\7<#J4:[,@K=^^3VI[(!F[Y"'\$^"\6CKH@5_6>/4H"$
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M',8=&D^/,,)H2!% .J$GFG!00>UU6*6TW-_K$ \ K1JEX.G9LZ7 F#*9S%Y
M>\N<KTP%0-Z2#NM8>KQ3,Z#$7LL<<\;WVWCN+T5SFEU3^5_X?PDFR$(!=K$P
M9SXQ2KK0-JCJ#FEN,;"%62;Q./QCA.6O ;M#;FB_PV=KM(EP:Z(%_!NCZ<D
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M-1S3=M-UZ+/XG\?GCQX-22V"2 *HNB%< /_:  P# 0 "$ ,0   0
M                  $@@$                       $@@ @  H,X
M            $@ !$  R@6W0   $P          $@$E D $$E!@   #D
M      $@@,$$@G\8      4DD        $DDG4D A4@      ;DD@  DDD@
M$@ '4D$D@@ $$  $J$D@$@  $D $D@D$$@ @D      &$D $$@@@$@$$  $@
MDD@$D @ @D@D $$$$ @ $D @@ $$ @$   DDD$ $D$DDDD$@$$ @ D$$ $@$
M$DD@$ @$$D @@$D@@$ @D$@  @DD D$$$DD @  $  D@DD@  @D@$@@ DDD@
M   @   $$@$  $  @   $   $@D@@$D  @ D$D$ $  D$@$@ D@@D@@ DD$@
M DD@ $ $@ D@ $$D $ $@   $$ D$DD@$DD  @D @DDD@$@@  D@  DD $@$
M@@$@@$DD $$  @@DD@$@@$D@ @$ $@$ $$@DD $$ DDD D$ @ DD@@@ $@$D
M D$@@ D$@  $ DD @$$@$D $@ @@D$ @4@@@@ $@$ D@ $D$  $D$ $$@$@0
M DD@$$@@@@ @$@ @$@D D@DD  0 $$ $@$$D $ $$D@D@ D$D$DDDGDDD@@D
M$@$DDD@ _\0 )Q ! 0$! 0$  @(" P " P   1$A #%!46$0@2!Q,$"A4)'!
MT?#_V@ ( 0$  3\0_P!*D!>)+P2P_P#:?+ERY<N7+ERY<N7+ERY<N7+ERY<N
M7(T@BQ;DI"2B7YQ3E/"C;"+@4#_VCERY<N7+ERY<N7+ERY<N7+ERY<N7+DW/
MJ*_/J>.@?R&VPQ18_:2QB@>%3 $)/*4!>&++RZA.MZ%RYL@C-U[P2KFB .C>
MJE43)"(R.VEN[0\:!]"3C_Y'^QWVN$L%U4>P*- CK2G$(2\4J6TV07!K"? V
M1!=YRX>S2F-"A*T.&D\97,'AZ  ]>]X#1W5'W?Q;_@;ON]5'G@@@"O(;M4YH
M0MH^2".R4'+D1,B !HQYPJ^X,B4O>8*:>H'*<7]D7#\?_%?V.^T^YF"@M@V*
M$/G2!J( 8:<B2H>GPD"* H*([$@ #A3OSGLV!K:V$%A[C[HUJE91%2TB'\M8
MJB%K4(,TT/&03=;E644357>B;7X>Q_B9"Y!#CVO"F#)%!EC>J8?2QI$*;+=$
MB%<HV(H(EB%-WBIZC>7*E 1@-7(+Z(JZ@] /N\^@V7"1Q)]$'_A_L?+T I2#
M*PBPXJC0H@!'1*G[_P"WOM41$=2P@;/P)$0'#N-J$NR)7=*AN$\1" '@E5HE
M!%%&&BH!BF&3;%FM3B[!425*N<0_:!+H&*=_$ T7 443A P"HE?\I-O]!G\%
M0.MN[/F,6J97I&?P(=S0H," _()A(  B&(BB/,GV),A02@8BA#LR[=3CMHHZ
MW,.!M1;7UO;+* :#U+%U@8&%1@@<8+J(*XCI(5()VFYV7R4,%?\ !_8H&A Q
M14/Q$.G0"<,/]Y!*^YR3/)GXD_[.^U$=GXT=$ 3 ?L@L^WTKE@)&,H'$9],=
MU"36.11Y:NL@<T @0T5FJ$(I:%!ZG5J0BXNJ:L4"B% /M(C3 VY9I%ZN:BGE
MP[!@Q(RL0(;A3 :XA5P/R(?OTS^*T[[74PL);G+EL^[,9BZ+9C63\(UFV"3
M!^P*.0S8YO5A0%0C'JFVN/$2+HX)@\@_^O\ E_L?@*/Y$7OPIS\\=0;<"[6
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M,.,496:TG=$6I%6@"H^U"+08Z &N8=,(:JBT4!0GDRQQ]@AB(!?"'\#!P_\
MU/Q_"Z"Y1@8HE \?-J[=1%L5B9M=>.SD\94D6#:^'@;_ %Q.?!@=,_QA'P-
M)JRO:SQZ^F$P4ZR4V(0'#4';C^G H$,!S6X0$@DUVDZIZ BZAKH8FUAQG^2H
M@-@_8-%@*@&5+ALL:@C?.!OS[2(9<0"-^D,])0G LV\0Q+@A4 !Y!J D04+3
M/X6":MTU5JI%*X/K\WJ5Y5 F)@I#22><<)= HU5C5Q1.:'*I#\*E44+!KMPT
MD* @I//9JZY.SEHE&E*+HC_"3/)G^I_$,AP,/J*\KI.E[W'^KG7Q2P]JW$\3
MJ9BB$I[*4""1AWV(Y8D(3!,,595P OP$#_0?R"JI9P!#]@ T# >AI@ AE5K
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MHB&+JY2Y@@0&,HS1$Q_DRU"@%VF*NA-.AZ#SL)R/^B(W-B]A6(W:BRB9RT(
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M+PR1J:& ;(A2'#M?I?=@-(@46OG()O'3(^1%7;$7!3DL!7"N?H%_KH _0,I
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MLJDJN^L)%9[W];_3/\._?O->Y+OSDGX9T<#_Q  G$  " 0,$ @(" P$
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M]7L;0? '0WV.X)ML0Z (%K 6<[([V%BY6M:]AX(HL1< /K\!4#[N-<^[A&@
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H)^G_ (<5Y:+X5%B+BL?SQT1Y!@D"+ ; ] #Z)_KY5Y%%1447G)3_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
